{"Clinical Trial ID": "NCT00259090", "Intervention": ["INTERVENTION 1:", "To succeed", "Fulvestant 500 mg once a month", "INTERVENTION 2:", "-Fulvestant + Anastrozole", "\u2022 Fulvestant 500 mg once a month per injection + Anastrozole 1 mg once a day per tablet"], "Eligibility": ["Incorporation criteria:", "Menopausal women.", "Biopsy confirms primary breast cancer.", "- Positive oestrogen receptor tumour.", "Suitable for surgery in a month.", "Informed written consent to participate in the study", "- Exclusion criteria:", "A previous treatment with any anti-hormonal treatment for breast cancer.", "A radiotherapy prior to the primary tumor.", "Previous chemotherapy for the primary tumour."], "Results": ["Performance measures:", "The rate of change in the reference H index at the time of surgery in the estrogen receptor (ER): Antitumor effects of Fulvestrant, Anastrozole and a combination of both, measured by the ER H index.", "For each sample, the ER H score is calculated from the percentage of very weak cell spots (+/-); low (+); moderate (++); or strong (+++) as follows: H-score = [(0.5 x percent +/-) + (1 x percent +) + (2 x percent ++) + (3 x percent +++)].", "Delay: Surgery (SRG) was to be performed between days 15 and 22 after starting treatment (BL)", "Results 1:", "Title of the arm/group: Fulvestrant", "Description of the arm/group: Fulvestant 500 mg once a month", "Total number of participants analysed: 35", "Average (standard error)", "Unit of measure: Percentage change from baseline -37 (4)", "Results 2:", "Title of the arm/group: Fulvestant + Anastrozole", "Description of the arm/group: Fulvestant 500 mg once a month per injection + Anastrozole 1 mg once a day per tablet", "Total number of participants analysed: 31", "Average (standard error)", "Unit of measure: Percentage change from baseline -38 (5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/40 (0.00 per cent)", "Pancytopenia 0/40 (0.00 %)", "Atrial fibrillation 0/40 (0.00 %)", "Inevitable event 0/40 (0.00 %)", "- Subcutaneous abscesses 0/40 (0.00 %)", "Procedural complication 0/40 (0.00 %)", "Adverse Events 2:", "Total: 3/40 (7.50 per cent)", "Pancytopenia 0/40 (0.00 %)", "Atrial fibrillation 1/40 (2.50%)", "Non-evaluable event 1/40 (2.50%)", "- Subcutaneous abscesses 0/40 (0.00 %)", "1/40 procedural complication (2.50%)"]}